Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

´Ù¹ß¼º°ñ¼öÁ¾ 56¿¹ÀÇ ÀÓ»óÀû ºÐ¼® ¹× Ä¡·á °á°ú A Clinical Study on Multiple Myeloma

´ëÇѾÏÇÐȸÁö 1995³â 27±Ç 5È£ p.869 ~ 878
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤Áø¿ì ±èÁ¤Èñ/±è½Ã¿µ/À±ÈÖÁß/Á¶°æ»ï

Abstract


Clinical findings and results were analysed in 56 cases diagnosed as multiple myeloma between October 1981 and June 1994 at Kyung Hee University Hospital.
@ES The results were as following:
1) The incidence reached a peak during 7th decade and male to female ratio was 1.2:1.
2) The chief complaints at initial presentation were bone pain(50%), pathologic fracture (14%) and anemia(14%).
3) Hematologic findings showed anemia in 77%, leukopenia in 25% and thrombocytopenia in 23%. ESR was elevated in 91% of patients. Hypercalcemia was noted in 13% and renal failure in 29%.
4) X-ray findings showed pathologic fracture in 39%, osteolytic lesion in 70% and osteoporosis in 32% but normal finding was found in 5% of patients
5) Clinical stage was stage I in 8%, stage ¥±in 19% and stage ¥²in 73% of patients. Fifteen of sixteen patients with renal insufficiency were in stage ¥².
6) Serum protein electrophoresis showed a M-peak in 89%. Mean M-protein. Concentration was 4.55g/dl. M-protein was IgG in 57%, IgA in 24%, IgD in 2% and light chain only in 17%. Kappa to lambda ratio was 1.4:1.
7) Variant forms of multiple myeloma were 2 cases of nonsecretory myeloma, 1 cases of solitary plasmacytoma and 1 case of plasma cell leukemia.
8) Response rate to primary chemotherapy was 37% for MP regimen and 60% for M2 regimen. There was statistically significant survival difference between responders and non-responders(p<0.01).
The overall median survival of patients was 76 weeks.

Å°¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS